1
|
Menegatti S, Potts B, Paredes R, Garcia-Alegria E, Baker SM, Kouskoff V. CD82 expression marks the endothelium to hematopoietic transition at the onset of blood specification in human. iScience 2023; 26:107583. [PMID: 37694151 PMCID: PMC10484973 DOI: 10.1016/j.isci.2023.107583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 06/20/2023] [Accepted: 08/03/2023] [Indexed: 09/12/2023] Open
Abstract
During embryonic development, all blood progenitors are initially generated from endothelial cells that acquire a hemogenic potential. Blood progenitors emerge through an endothelial-to-hematopoietic transition regulated by the transcription factor RUNX1. To date, we still know very little about the molecular characteristics of hemogenic endothelium and the molecular changes underlying the transition from endothelium to hematopoiesis. Here, we analyzed at the single cell level a human embryonic stem cell-derived endothelial population containing hemogenic potential. RUNX1-expressing endothelial cells, which harbor enriched hemogenic potential, show very little molecular differences to their endothelial counterpart suggesting priming toward hemogenic potential rather than commitment. Additionally, we identify CD82 as a marker of the endothelium-to-hematopoietic transition. CD82 expression is rapidly upregulated in newly specified blood progenitors then rapidly downregulated as further differentiation occurs. Together our data suggest that endothelial cells are first primed toward hematopoietic fate, and then rapidly undergo the transition from endothelium to blood.
Collapse
Affiliation(s)
- Sara Menegatti
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
- CytoSeek Ltd, Unit Dx, Albert Road, Bristol BS2 0XJ, UK
| | - Bethany Potts
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
| | - Roberto Paredes
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
| | - Eva Garcia-Alegria
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
| | - Syed Murtuza Baker
- Division of Informatics, Imaging & Data Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK
| | - Valerie Kouskoff
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
| |
Collapse
|
2
|
Johnson PA, Menegatti S, Chambers AC, Alibhai D, Collard TJ, Williams AC, Bayley H, Perriman AW. A rapid high throughput bioprinted colorectal cancer spheroid platform for in vitrodrug- and radiation-response. Biofabrication 2022; 15:014103. [PMID: 36321254 DOI: 10.1088/1758-5090/ac999f] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 10/12/2022] [Indexed: 11/07/2022]
Abstract
We describe the development of a high-throughput bioprinted colorectal cancer (CRC) spheroid platform with high levels of automation, information content, and low cell number requirement. This is achieved via the formulation of a hydrogel bioink with a compressive Young's modulus that is commensurate with that of colonic tissue (1-3 kPa), which supports exponential growth of spheroids from a wide range of CRC cell lines. The resulting spheroids display tight cell-cell junctions, bioink matrix-cell interactions and necrotic hypoxic cores. By combining high content light microscopy imaging and processing with rapid multiwell plate bioprinting, dose-response profiles are generated from CRC spheroids challenged with oxaliplatin (OX) and fluorouracil (5FU), as well as radiotherapy. Bioprinted CRC spheroids are shown to exhibit high levels of chemoresistance relative to cell monolayers, and OX was found to be significantly less effective against tumour spheroids than in monolayer culture, when compared to 5FU.
Collapse
Affiliation(s)
- Peter A Johnson
- Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom
| | - Sara Menegatti
- School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom
| | - Adam C Chambers
- School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom
| | - Dominic Alibhai
- Wolfson Bioimaging Facility, University of Bristol, Bristol BS8 1TD, United Kingdom
| | - Tracey J Collard
- School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom
| | - Ann C Williams
- School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom
| | - Hagan Bayley
- Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom
| | - Adam W Perriman
- School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom
| |
Collapse
|
3
|
Menegatti S, Potts B, Garcia-Alegria E, Paredes R, Lie-A-Ling M, Lacaud G, Kouskoff V. The RUNX1b Isoform Defines Hemogenic Competency in Developing Human Endothelial Cells. Front Cell Dev Biol 2021; 9:812639. [PMID: 34977046 PMCID: PMC8716778 DOI: 10.3389/fcell.2021.812639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 12/01/2021] [Indexed: 11/13/2022] Open
Abstract
The transcription factor RUNX1 is a master regulator of blood cell specification. During embryogenesis, hematopoietic progenitors are initially generated from hemogenic endothelium through an endothelium-to-hematopoietic transition controlled by RUNX1. Several studies have dissected the expression pattern and role of RUNX1 isoforms at the onset of mouse hematopoiesis, however the precise pattern of RUNX1 isoform expression and biological output of RUNX1-expressing cells at the onset of human hematopoiesis is still not fully understood. Here, we investigated these questions using a RUNX1b:VENUS RUNX1c:TOMATO human embryonic stem cell line which allows multi-parameter single cell resolution via flow cytometry and isolation of RUNX1b-expressing cells for further analysis. Our data reveal the sequential expression of the two RUNX1 isoforms with RUNX1b expressed first in a subset of endothelial cells and during the endothelial to hematopoietic transition while RUNX1c only becomes expressed in fully specified blood cells. Furthermore, our data show that RUNX1b marks endothelial cells endowed with hemogenic potential and that RUNX1b expression level determines hemogenic competency in a dose-dependent manner. Together our data reveal the dynamic of RUNX1 isoforms expression at the onset of human blood specification and establish RUNX1b isoform as the earliest known marker for hemogenic competency.
Collapse
Affiliation(s)
- Sara Menegatti
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
- CytoSeek Ltd., Bristol, United Kingdom
| | - Bethany Potts
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
| | - Eva Garcia-Alegria
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
- Stem Cell Process Development, Adaptimmune Ltd., Abingdon, United Kingdom
| | - Roberto Paredes
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
| | - Michael Lie-A-Ling
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom
| | - Georges Lacaud
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom
| | - Valerie Kouskoff
- Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
| |
Collapse
|
4
|
Garcia-Alegria E, Potts B, Menegatti S, Kouskoff V. In vitro differentiation of human embryonic stem cells to hemogenic endothelium and blood progenitors via embryoid body formation. STAR Protoc 2021; 2:100367. [PMID: 33718891 PMCID: PMC7933812 DOI: 10.1016/j.xpro.2021.100367] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Little is known about the emergence of blood progenitors during human embryogenesis due to ethical reasons and restricted embryo access. The use of human embryonic stem cells (hESCs) as a model system offers unique opportunities to dissect human blood cell formation. Here, we describe a protocol allowing the differentiation of hESCs via embryoid bodies toward hemogenic endothelium and its subsequent differentiation to blood progenitors. This protocol relies on the formation of embryoid bodies, which is tricky if not carefully performed. For complete details on the use and execution of this protocol, please refer to Garcia-Alegria et al. (2018).
Collapse
Affiliation(s)
- Eva Garcia-Alegria
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
- Stem Cell Process Development, Adaptimmune Ltd., 60 Jubilee Avenue Milton Park, Abingdon, Oxfordshire OX14 4RX, UK
| | - Bethany Potts
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
| | - Sara Menegatti
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
- CytoSeek Ltd, Unit Dx, Albert Road, Bristol BS2 0XJ, UK
| | - Valerie Kouskoff
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester M13 9PT, UK
| |
Collapse
|
5
|
Schneible JD, Young AT, Daniele MA, Menegatti S. Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids. Pharm Res 2020; 37:142. [PMID: 32661774 PMCID: PMC7983306 DOI: 10.1007/s11095-020-02864-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Accepted: 06/23/2020] [Indexed: 02/07/2023]
Abstract
PURPOSE This study aimed to develop a hydrogel system for treating aggressive triple negative breast cancer (TNBC) via kinetically-controlled delivery of the synergistic drug pair doxorubicin (DOX) and gemcitabine (GEM). A 2D assay was adopted to evaluate therapeutic efficacy by determining combination index (CI), and a 3D assay using cancer spheroids was implemented to assess the potential for translation in vivo. METHODS The release of DOX and GEM from an acetylated-chitosan (ACS, degree of acetylation χAc = 40 ± 5%) was characterized to identify a combined drug loading that affords release kinetics and dose that are therapeutically synergistic. The selected DOX/GEM-ACS formulation was evaluated in vitro with 2-D and 3-D models of TNBC to determine the combination index (CI) and the tumor volume reduction, respectively. RESULTS Therapeutically desired release dosages and kinetics of GEM and DOX were achieved. When evaluated with a 2-D model of TNBC, the hydrogel afforded a CI of 0.14, indicating a stronger synergism than concurrent administration of DOX and GEM (CI = 0.23). Finally, the therapeutic hydrogel accomplished a notable volume reduction of the cancer spheroids (up to 30%), whereas the corresponding dosages of free drugs only reduced growth rate. CONCLUSIONS The ACS hydrogel delivery system accomplishes drug release kinetics and molar ratio that affords strong therapeutically synergism. These results, in combination with the choice of ACS as affordable and highly abundant source material, provide a strong pre-clinical demonstration of the potential of the proposed system for complementing surgical resection of aggressive solid tumors.
Collapse
Affiliation(s)
- John D Schneible
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA
| | - Ashlyn T Young
- Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina, Chapel Hill, North Carolina, USA
| | - M A Daniele
- Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Electrical and Computer Engineering, North Carolina State University, 890 Oval Drive, Raleigh, North Carolina, USA.
| | - S Menegatti
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
- Biomanufacturing Training and Education Center, North Carolina State University, 850 Oval Dr, Raleigh, North Carolina, USA.
| |
Collapse
|
6
|
Menegatti S, de Kruijf M, Garcia‐Alegria E, Lacaud G, Kouskoff V. Transcriptional control of blood cell emergence. FEBS Lett 2019; 593:3304-3315. [PMID: 31432499 PMCID: PMC6916194 DOI: 10.1002/1873-3468.13585] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 08/09/2019] [Accepted: 08/14/2019] [Indexed: 01/06/2023]
Abstract
The haematopoietic system is established during embryonic life through a series of developmental steps that culminates with the generation of haematopoietic stem cells. Characterisation of the transcriptional network that regulates blood cell emergence has led to the identification of transcription factors essential for this process. Among the many factors wired within this complex regulatory network, ETV2, SCL and RUNX1 are the central components. All three factors are absolutely required for blood cell generation, each one controlling a precise step of specification from the mesoderm germ layer to fully functional blood progenitors. Insight into the transcriptional control of blood cell emergence has been used for devising protocols to generate blood cells de novo, either through reprogramming of somatic cells or through forward programming of pluripotent stem cells. Interestingly, the physiological process of blood cell generation and its laboratory-engineered counterpart have very little in common.
Collapse
Affiliation(s)
- Sara Menegatti
- Developmental Haematopoiesis GroupFaculty of Biology, Medicine and Healththe University of ManchesterUK
| | - Marcel de Kruijf
- Developmental Haematopoiesis GroupFaculty of Biology, Medicine and Healththe University of ManchesterUK
| | - Eva Garcia‐Alegria
- Developmental Haematopoiesis GroupFaculty of Biology, Medicine and Healththe University of ManchesterUK
| | - Georges Lacaud
- Cancer Research UK Stem Cell Biology GroupCancer Research UK Manchester InstituteThe University of ManchesterMacclesfieldUK
| | - Valerie Kouskoff
- Developmental Haematopoiesis GroupFaculty of Biology, Medicine and Healththe University of ManchesterUK
| |
Collapse
|
7
|
Garcia-Alegria E, Menegatti S, Fadlullah MZH, Menendez P, Lacaud G, Kouskoff V. Early Human Hemogenic Endothelium Generates Primitive and Definitive Hematopoiesis In Vitro. Stem Cell Reports 2018; 11:1061-1074. [PMID: 30449319 PMCID: PMC6234921 DOI: 10.1016/j.stemcr.2018.09.013] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 09/24/2018] [Accepted: 09/25/2018] [Indexed: 01/11/2023] Open
Abstract
The differentiation of human embryonic stem cells (hESCs) to hematopoietic lineages initiates with the specification of hemogenic endothelium, a transient specialized endothelial precursor of all blood cells. This in vitro system provides an invaluable model to dissect the emergence of hematopoiesis in humans. However, the study of hematopoiesis specification is hampered by a lack of consensus in the timing of hemogenic endothelium analysis and the full hematopoietic potential of this population. Here, our data reveal a sharp decline in the hemogenic potential of endothelium populations isolated over the course of hESC differentiation. Furthermore, by tracking the dynamic expression of CD31 and CD235a at the onset of hematopoiesis, we identified three populations of hematopoietic progenitors, representing primitive and definitive subsets that all emerge from the earliest specified hemogenic endothelium. Our data establish that hemogenic endothelium populations endowed with primitive and definitive hematopoietic potential are specified simultaneously from the mesoderm in differentiating hESCs.
Collapse
Affiliation(s)
- Eva Garcia-Alegria
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK
| | - Sara Menegatti
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK
| | - Muhammad Z H Fadlullah
- Stem Cell Biology Group, CRUK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK
| | - Pablo Menendez
- Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Instituciò Catalana Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Georges Lacaud
- Stem Cell Biology Group, CRUK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
| | - Valerie Kouskoff
- Developmental Haematopoiesis Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK.
| |
Collapse
|
8
|
Garcia-Alegria E, Menegatti S, Batta K, Cuvertino S, Florkowska M, Kouskoff V. Emerging concepts for the in vitro derivation of murine haematopoietic stem and progenitor cells. FEBS Lett 2016; 590:4116-4125. [PMID: 27404333 DOI: 10.1002/1873-3468.12300] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 07/04/2016] [Accepted: 07/09/2016] [Indexed: 02/11/2024]
Abstract
Well into the second decade of the 21st century, the field of regenerative medicine is bursting with hopes and promises to heal young and old. The bespoken generation of cells is thought to offer unprecedented cures for a vast range of diseases. Haematological disorders have already benefited tremendously from stem cell therapy in the form of bone marrow transplantation. However, lack of compatible donors often means that patients remain on transplantation waiting lists for too long. The in vitro derivation of haematopoietic stem cells offers the possibility to generate tailor-made cells for the treatment of these patients. Promising approaches to generate in vitro-derived blood progenitors include the directed differentiation of pluripotent stem cells and the reprogramming of somatic cells.
Collapse
Affiliation(s)
- Eva Garcia-Alegria
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, UK
| | - Sara Menegatti
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, UK
| | - Kiran Batta
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, UK
| | - Sara Cuvertino
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, UK
| | - Magdalena Florkowska
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, UK
| | - Valerie Kouskoff
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, UK
| |
Collapse
|
9
|
Wojnilowicz M, Tortora M, Bobay BG, Santiso E, Caruso M, Micheli L, Venanzi M, Menegatti S, Cavalieri F. A combined approach for predicting the cytotoxic effect of drug-nanoaggregates. J Mater Chem B 2016; 4:6516-6523. [PMID: 32263696 DOI: 10.1039/c6tb02105k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We present a combined spectroscopic and computational approach aimed to elucidate the mechanism of formation and activity of etoposide nanoaggregates upon release from dextran-etoposide conjugates. Etoposide is an anticancer drug that inhibits cell growth by blocking Topoisomerase II, the key enzyme involved in re-ligation of the DNA chains during the replication process. In silico and spectroscopic analysis indicate that released etoposide nanoaggregates have a different structure, stability, and bioactivity, which depend on the pH experienced during the release. Molecular dynamics simulation and in silico docking of etoposide dimers suggest that the aggregation phenomena inhibit etoposide bioactivity, yet without drastically preventing Topoisomerase II binding. We correlated the diminished cytotoxic activity exerted by dextran-etoposide conjugates on the A549 lung cancer cells, compared to the free drug, to the formation and stability of drug nanoaggregates.
Collapse
Affiliation(s)
- M Wojnilowicz
- Department of Chemical and Biomolecular Engineering, The University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Batta K, Menegatti S, Garcia-Alegria E, Florkowska M, Lacaud G, Kouskoff V. Concise Review: Recent Advances in the In Vitro Derivation of Blood Cell Populations. Stem Cells Transl Med 2016; 5:1330-1337. [PMID: 27388244 PMCID: PMC5031184 DOI: 10.5966/sctm.2016-0039] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Accepted: 04/18/2016] [Indexed: 12/21/2022] Open
Abstract
: Hematopoietic cell-based therapies are currently available treatment options for many hematological and nonhematological disorders. However, the scarcity of allogeneic donor-derived cells is a major hurdle in treating these disorders. Embryonic stem cell-based directed differentiation and direct reprogramming of somatic cells provide excellent tools for the potential generation of hematopoietic stem cells usable in the clinic for cellular therapies. In addition to blood stem cell transplantation, mature blood cells such as red blood cells, platelets, and engineered T cells have also been increasingly used to treat several diseases. Besides cellular therapies, induced blood progenitor cells generated from autologous sources (either induced pluripotent stem cells or somatic cells) can be useful for disease modeling of bone marrow failures and acquired blood disorders. However, although great progress has been made toward these goals, we are still far from the use of in vitro-derived blood products in the clinic. We review the current state of knowledge on the directed differentiation of embryonic stem cells and the reprogramming of somatic cells toward the generation of blood stem cells and derivatives. SIGNIFICANCE Hematopoietic cell-based therapies are currently available treatment options for many hematological and nonhematological disorders. However, the scarcity of allogeneic donor-derived cells is a major hurdle in treating these disorders. The current state of knowledge on the directed differentiation of embryonic stem cells and the reprogramming of somatic cells toward the generation of blood stem cells and derivatives is reviewed.
Collapse
Affiliation(s)
- Kiran Batta
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
| | - Sara Menegatti
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
| | - Eva Garcia-Alegria
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
| | - Magdalena Florkowska
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
| | - Georges Lacaud
- Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
| | - Valerie Kouskoff
- Cancer Research UK Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
| |
Collapse
|
11
|
Thambyrajah R, Patel R, Mazan M, Lie-a-Ling M, Lilly A, Eliades A, Menegatti S, Garcia-Alegria E, Florkowska M, Batta K, Kouskoff V, Lacaud G. New insights into the regulation by RUNX1 and GFI1(s) proteins of the endothelial to hematopoietic transition generating primordial hematopoietic cells. Cell Cycle 2016; 15:2108-2114. [PMID: 27399214 PMCID: PMC4993433 DOI: 10.1080/15384101.2016.1203491] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/07/2016] [Accepted: 06/09/2016] [Indexed: 10/26/2022] Open
Abstract
The first hematopoietic cells are generated very early in ontogeny to support the growth of the embryo and to provide the foundation to the adult hematopoietic system. There is a considerable therapeutic interest in understanding how these first blood cells are generated in order to try to reproduce this process in vitro. This would allow generating blood products, or hematopoietic cell populations from embryonic stem (ES) cells, induced pluripotent stem cells or through directed reprogramming. Recent studies have clearly established that the first hematopoietic cells originate from a hemogenic endothelium (HE) through an endothelial to hematopoietic transition (EHT). The molecular mechanisms underlining this transition remain largely unknown with the exception that the transcription factor RUNX1 is critical for this process. In this Extra Views report, we discuss our recent studies demonstrating that the transcriptional repressors GFI1 and GFI1B have a critical role in the EHT. We established that these RUNX1 transcriptional targets are actively implicated in the downregulation of the endothelial program and the loss of endothelial identity during the formation of the first blood cells. In addition, our results suggest that GFI1 expression provides an ideal novel marker to identify, isolate and study the HE cell population.
Collapse
Affiliation(s)
- Roshana Thambyrajah
- CRUK Stem Cell Biology, Cancer Research UK Manchester Institute, Manchester, UK
| | - Rahima Patel
- CRUK Stem Cell Biology, Cancer Research UK Manchester Institute, Manchester, UK
| | - Milena Mazan
- CRUK Stem Cell Biology, Cancer Research UK Manchester Institute, Manchester, UK
| | - Michael Lie-a-Ling
- CRUK Stem Cell Biology, Cancer Research UK Manchester Institute, Manchester, UK
| | - Andrew Lilly
- CRUK Stem Cell Haematopoiesis, Cancer Research UK Manchester Institute, Manchester, UK
| | - Alexia Eliades
- CRUK Stem Cell Haematopoiesis, Cancer Research UK Manchester Institute, Manchester, UK
| | - Sara Menegatti
- CRUK Stem Cell Haematopoiesis, Cancer Research UK Manchester Institute, Manchester, UK
| | - Eva Garcia-Alegria
- CRUK Stem Cell Haematopoiesis, Cancer Research UK Manchester Institute, Manchester, UK
| | | | - Kiran Batta
- CRUK Stem Cell Biology, Cancer Research UK Manchester Institute, Manchester, UK
| | - Valerie Kouskoff
- CRUK Stem Cell Haematopoiesis, Cancer Research UK Manchester Institute, Manchester, UK
| | - Georges Lacaud
- CRUK Stem Cell Biology, Cancer Research UK Manchester Institute, Manchester, UK
| |
Collapse
|
12
|
Rogge L, Menegatti S, Latis E, Yahia H, Leloup C, Ménagé N, Moltό A, Miceli-Richard C, Dougados M, Bianchi E. OP0111 Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Rosine N, Menegatti S, Leloup C, Latis E, Bianchi E, Dougados M, Rogge L. AB0123 Immunophenotyping of Lymphocyte Populations by Hyperspectral Cytrometry on Patients with Spondyloarthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Yvernogeau L, Gautier R, Khoury H, Menegatti S, Schmidt M, Gilles JF, Jaffredo T. An in vitro model of hemogenic endothelium commitment and hematopoietic production. Development 2016; 143:1302-12. [PMID: 26952980 DOI: 10.1242/dev.126714] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Accepted: 02/21/2016] [Indexed: 01/03/2023]
Abstract
Adult-type hematopoietic stem and progenitor cells are formed during ontogeny from a specialized subset of endothelium, termed the hemogenic endothelium, via an endothelial-to-hematopoietic transition (EHT) that occurs in the embryonic aorta and the associated arteries. Despite efforts to generate models, little is known about the mechanisms that drive endothelial cells to the hemogenic fate and about the subsequent molecular control of the EHT. Here, we have designed a stromal line-free controlled culture system utilizing the embryonic pre-somitic mesoderm to obtain large numbers of endothelial cells that subsequently commit into hemogenic endothelium before undergoing EHT. Monitoring the culture for up to 12 days using key molecular markers reveals stepwise commitment into the blood-forming system that is reminiscent of the cellular and molecular changes occurring during hematopoietic development at the level of the aorta. Long-term single-cell imaging allows tracking of the EHT of newly formed blood cells from the layer of hemogenic endothelial cells. By modifying the culture conditions, it is also possible to modulate the endothelial cell commitment or the EHT or to produce smooth muscle cells at the expense of endothelial cells, demonstrating the versatility of the cell culture system. This method will improve our understanding of the precise cellular changes associated with hemogenic endothelium commitment and EHT and, by unfolding these earliest steps of the hematopoietic program, will pave the way for future ex vivo production of blood cells.
Collapse
Affiliation(s)
- Laurent Yvernogeau
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, UMR 7622, Laboratoire de Biologie du Développement, Paris 75005, France CNRS, UMR 7622, Inserm U 1156, IBPS, Laboratoire de Biologie du Développement, Paris 75005, France
| | - Rodolphe Gautier
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, UMR 7622, Laboratoire de Biologie du Développement, Paris 75005, France CNRS, UMR 7622, Inserm U 1156, IBPS, Laboratoire de Biologie du Développement, Paris 75005, France
| | - Hanane Khoury
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, UMR 7622, Laboratoire de Biologie du Développement, Paris 75005, France CNRS, UMR 7622, Inserm U 1156, IBPS, Laboratoire de Biologie du Développement, Paris 75005, France
| | - Sara Menegatti
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, UMR 7622, Laboratoire de Biologie du Développement, Paris 75005, France CNRS, UMR 7622, Inserm U 1156, IBPS, Laboratoire de Biologie du Développement, Paris 75005, France
| | - Melanie Schmidt
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, UMR 7622, Laboratoire de Biologie du Développement, Paris 75005, France CNRS, UMR 7622, Inserm U 1156, IBPS, Laboratoire de Biologie du Développement, Paris 75005, France
| | - Jean-Francois Gilles
- Institute of Biology Paris-Seine, Sorbonne Universités, UPMC Univ Paris 06, Cellular Imaging Facility, Paris 75005, France
| | - Thierry Jaffredo
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, UMR 7622, Laboratoire de Biologie du Développement, Paris 75005, France CNRS, UMR 7622, Inserm U 1156, IBPS, Laboratoire de Biologie du Développement, Paris 75005, France
| |
Collapse
|